VNDA 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

VNDA ▼ -4.69% at T+20d

NEUTRAL call ✗ call lost -4.69% · α vs SPY -7.83% · entry $6.39 → $6.09

Next anchor: T+60d in 7w

Currently $5.87 · -8.14% from $6.39 entry

Entry anchored
May 6, 03:59 PM ET
via Databento tick

T+1d

0.00%

call 0.00% · α -0.83%

$6.39

settled 5w ago

T+5d

+0.63%

call +0.63% · α -0.88%

$6.43

settled 4w ago

T+20d

-4.69%

call -4.69% · α -7.83%

$6.09

settled 9d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Vanda Pharmaceuticals reported Q1 2026 revenue of $51.7M (+3% YoY), in line with modest growth, but EPS of -$0.82 missed the Street consensus of -$0.53 by 55% as net loss widened to $48.6M. Positives include 26% Fanapt growth, FDA approval of BYSANTI, NEREUS launch, and raised FY2026 revenue guidance to $240-290M (from $230-260M). The mixed results balance a significant EPS miss against strong pipeline and commercial catalysts.

Key Financial Metrics

Guidance

$240 million to $290 million

raised

Gross Margin

93.89%

Actionable Insight

The EPS miss may drive short-term selling pressure, but the raised guidance and new product approvals (BYSANTI, NEREUS) provide upside catalysts. Monitor NEREUS and BYSANTI revenue trajectories in Q2 2026 for sustainable growth. Cash burn remains a concern.

Key Facts

Q1 2026 total revenue $51.7M, up 3% YoY from $50.0M
Fanapt net product sales $29.6M, up 26% YoY
GAAP diluted EPS -$0.82 vs consensus -$0.53 (miss of 54.7%)
Net loss $48.6M vs $29.5M in Q1 2025
Cash and equivalents $202.3M, down $61.5M including $10M milestone to Eli Lilly
FY2026 revenue guidance raised to $240-290M (from $230-260M), including $10-30M from NEREUS
BYSANTI (milsaperidone) received FDA approval on Feb 20, 2026
NEREUS (tradipitant) launched via direct-to-consumer platform

Financial Impact

EPS miss of 54.7% vs consensus; revenue slightly above prior year but below undisclosed estimate; cash burn $61.5M in quarter

epsnet losscashrevenue guidance

Risk Factors

Cash burn rate accelerated ($61.5M in Q1); runway limited despite $202.3M balance
HETLIOZ sales declining 24% YoY, eroding base revenue
Execution risk for NEREUS and BYSANTI commercial launches
Heavy reliance on Fanapt for growth; pipeline products still early stage

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

82% bullish (11 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001628280-26-031241
Document: vnda-20260506.htm	0001628280-26-031241
Document: 0001628280-26-031241-index-headers.html	0001628280-26-031241
Document: 0001628280-26-031241-index.html	0001628280-26-031241
Document: 0001628280-26-031241.txt	0001628280-26-031241
8-K Data (Synthetic)	0001628280-26-031241

US Market Status

Market Closed — Opens Mon (45h 38m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access